GOLDENWELL BIOTECH, INC. (GWLL) stock: key figures, P/E, revenue and dividend

Consumer Staples · United States · ISIN US38138N1046

Price
0.65 USD
Market cap
64.35 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

GOLDENWELL BIOTECH, INC. financials

Fiscal year2025
Revenue55.00 USD
Gross profit12.00 USD
Operating income-113,326.00 USD
EBIT-288,071.00 USD
Net income-296,471.00 USD
Diluted EPS – continuing operations0.00 USD

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About GOLDENWELL BIOTECH, INC.

Goldenwell Biotech, Inc. engages in the nutraceutical and dietary supplements business. It offers JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Solon, Ohio.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.